INTRODUCTION
============

Cardiac myxomas are rare. The classical clinical manifestations of cardiac myxomas can be a triad with constitutional, obstructive and embolic symptoms^\[[@r1]\]^. The infected cardiac myxoma is a very rare condition with only sporadic cases reported in the literature. In 1998, Revankar & Clark^\[[@r2]\]^ presented a complete literature collection of infected cardiac myxoma with a total of 40 cases, with detailed descriptions of the clinical features of this rare condition. They found no clear distinction between infected and uninfected cardiac myxomas, however, the infected myxomas are associated with more febrile symptoms and a higher risk of embolic events. In order to highlight the recent trends of infected cardiac myxoma, an updated review is made based on a renewed literature collection.

METHODS
=======

A comprehensive literature search was conducted on MEDLINE, Highwire Press and Google between 1998 and 2014. The search terms included \"myxoma\", \"heart\", \"heart valve\", \"endocarditis\", \"infected\", \"bacteremia\", \"blood culture\" and \"sepsis\". Data were extracted from the text, figures and tables, with details of the study population, demographics, onset symptom, duration of disease, risk factor, complication, microorganism, antibiotic use and surgical treatment, timing of surgical operation, follow-up duration and main outcomes including survival, postoperative complication, requirement of further surgical procedure and mortality.

Reference values of white blood cell count, hemoglobin, erythrocyte sedimentation rate and C-reaction protein were 4.0-10.0×10^9^/L, \>12 g/dL (\>11 g/dL for females), \<20 mm/h and 0-1 mg/dL, respectively.

Quantitative data were presented as mean±standard deviation with range and median values, and intergroup differences were compared using the unpaired *t* test. Frequencies were compared using Fisher\'s exact test. Results with *P*\<0.05 were considered statistically significant.

Patients\' information
----------------------

A total of 39 reports^\[[@r3]-[@r41]\]^ in terms of infected cardiac myxoma were collected and these involved 39 patients. Their information was listed in [Table 1](#t1){ref-type="table"}. According to the diagnostic criteria of infected cardiac myxoma, 34 (87.2%) were definite^\[[@r3]-[@r36]\]^, 4 (10.3%) were probable^\[[@r37]-[@r40]\]^ and 1 (2.6%) was possible^\[[@r41]\]^, with a compatible distribution of the three-level infected cardiac myxomas reported by Revankar & Clark^\[[@r2]\]^. The locations of the infected cardiac myxomas were left atrium 27 (69.2%), right atrium 5 (12.8%), mitral valve 5 (12.8%), right ventricle 1 (2.6%) and unstated 1 (2.6%), also similar to the percentages of the locations reported by Revankar & Clark^\[[@r2]\]^. The only difference was a lack of biatrial myxomas in the present series but with multiple left atrial myxomas instead. There were 23 (62.2%) males and 14 (37.8%) females (*x*^2^=4.4, *P*=0.062) with a male-to-female ratio of 1.64, while gender of 2 patients was not given. Their ages were 49.2±15.7 (range, 12-74; median,52) years *(n*=37). No age difference was found between male and female patients (50.7±11.4 years *vs.* 46.9±21.3 years, *P*=0.4786).

###### 

Summary of 39 patients with infected cardiac myxoma

  Serial N^o^   Year   Author            Sex   Age   Microorganism                                                     Diagnostic means            Location of myxoma               Operation   Outcome
  ------------- ------ ----------------- ----- ----- ----------------------------------------------------------------- --------------------------- -------------------------------- ----------- ----------------------------
  Definite                                                                                                                                                                                      
  1             2011   Adamira           F     58    *Staphylococcus* & *Enterococcus faecalis*                        TTE,TEE                     LAx2                             Yes         Survived
  2             2006   Awab              M     58    *Histoplasma capsulatum*                                          TTE                         LA                               Yes         Survived
  3             2011   Belgi Yildirim    M     47    *Streptococcus viridans*                                          TTE                         LA                               Yes         Survived
  4             2010   Bhanot            M     54    *Staphylococcus lugdunensis*                                      CT, TEE                     LA                               Yes         Survived
  5             2001   Brazill           M     52    *Streptococci viridans*                                           TTE, TEE                    LA                               Yes         Survived
  6             2007   Chan              M     44    *Streptococcus viridans*                                          TTE                         RV                               Yes         Survived
  7             2011   Chang             M     49    *Streptococcus bovis*                                             TTE, TEE                    LA                               Yes         Survived
  8             2001   Dekkers           M     40    *Streptococcus mutans*                                            TTE, TEE                    LA                               Yes         Survived
  9             2008   Falasca           F     63    *Staphylococcus spp*                                              TTE                         LA                               Yes         Survived
  10            2013   Furukawa          M     62    *Streptococcus agalactiae*                                        TTE, TEE                    LA                               Yes         Survived
  11            2005   García-Quintana   F     58    *Streptococcus oralis*                                            TTE                         LA                               Yes         Survived
  12            2004   Gregory           M     43    MSSA                                                              TTE (-), TEE (+)            LA                               Yes         Survived
  13            2007   Guler             F     12    MSSA                                                              TTE                         MV (AML)                         Yes         Survived
  14            2008   Janion            M     67    MRSA                                                              TTE                         LA                               Yes         Survived
  15            2005   Juang             M     42    G-positive cocci                                                  TEE                         LA                               Yes         Survived
  16            2004   Karachalios       M     55    *Streptococcus viridans*                                          TTE                         LA                               Yes         Survived
  17            2007   Leone             F     74    *Enterococcus faecalis*                                           TTE                         LA                               Yes         Survived
  18            2013   Nagata            M     66    *Streptococcus mitis*                                             TEE                         LA                               Yes         Survived
  19            2001   Oyama             M     57    MRSA                                                              TTE                         LA                               Yes         Survived
  20            2004   Parks             M     36    *Staphylococcus aureus*(oxacillin-resistant) (ORSA)               TTE                         RA                               Yes         Survived
  21            2002   Prince            F     12    *Streptococcus viridans*                                          TTE                         LA                               Yes         Survived
  22            2001   Puvaneswary       M     50    *Streptococcus viridans & Streptococcus salivarius*               TTE (-), TEE (+)            RA                               Yes         Survived
  23            2006   Quigley           M     55    *Streptococcus mutans*                                            TEE                         LA                               Yes         Survived
  24            2005   Riad              M     36    MRSA                                                              TTE                         RA                               Yes         Survived
  25            2010   Sasaki            M     69    *Klebsiella pneumoniae*                                           TEE                         LA                               Yes         Survived
  26            2010   Surovcík          F     59    *Enterococcus faecalis*                                           TTE, TEE, CT                LA                               Yes         Survived
  27            2002   Tanaka            F     70    *Enterococcus faecalis*                                           TEE                         LA                               Yes         Survived
  28            1999   Toda              M     20    Bacterial colonies                                                TTE                         MV (PML, posterior commissure)   Yes         Survived
  29            2009   Trimeche          F     46    MSSA                                                              TTE, TEE                    LA                               NG          Died
  30            2002   Uchino            F     47    *Streptococcus bovis*                                             TTE                         LA                               NG          Survived
  31            2006   Veitch            F     35    *Staphylococcus aureus*                                           TTE, TEE                    MV (AML)                         Yes         Survived
  32            2011   Yoshioka          M     52    MSSA                                                              TTE                         LA                               Yes         Survived
  33            2006   Zechini           M     55    Catalase-negative microorganisms (G-positive cocci by staining)   TTE, TEE                    LA                               NG          Survived
  34            2013   Zwinkels          ?           *Streptococcus* (Group C)                                         TTE, cardiac CT angiogram   RA                               Yes         Survived
  Probable                                                                                                                                                                                      
  35            2007   Bernstein         F     60    *Streptococcus mitis*                                             TEE                         MV (PML)                         Yes         Survived
  36            2005   Liu               F     12    *Neisseria lactamica*                                             TTE                         MV (AML)                         Yes         Survived
  37            1998   Marshall          F     50    *Actinobacillus* *actinomycetemcomitans*                          TTE                         LA                               Yes         Survived
  38            2001   Pinede            ?           *Streptococcus viridans*                                          ?                           ?                                Yes         Survived
  Possible                                                                                                                                                                                      
  39            2005   Despott           M     57    *Klebsiella pneumoniae*                                           TTE                         RA                               No          Died of right lung abscess

AML=anterior mitral leaflet; CT=computed tomography; F=female; LA=left atrium; M=male; MRSA=methicillin-resistant Staphylococcus aureus; MSSA=methicillin-sensitive Staphylococcus aureus; MV=mitral valve; NG=not given; PML= posterior mitral leaflet; RA=right atrium; TEE=transesophageal echocardiography; TTE= transthoracic echocardiography

Risk factors
------------

Recent dental procedures, recent infections, previous invasive procedures and immunocompromised conditions were the risk factors that led to a cardiac myxoma infected. No predominance was noted between the above risk factors. No significant difference was found in each risk factor between the present series and the series of Revankar & Clark^\[[@r2]\]^ ([Table 2](#t2){ref-type="table"}).

###### 

Risk factors.

  Risk factor                                                                                      Present     Revankar & Clark\'s   *x*^2^   *P* value
  ------------------------------------------------------------------------------------------------ ----------- --------------------- -------- -----------
  Recent dental problem                                                                            3 (7.7)     9 (22)                3.4      0.115
      Dental surgery                                                                               1                                           
      Reconstructive dental procedures; coronary catheterization and angioplasty 2 years earlier   1                                           
      Dental decay                                                                                 1                                           
  Recent infection                                                                                 4 (10.3)    4 (10)                0.0      1.000
      Achilles tendon infection                                                                    2                                           
      Urinary tract infection                                                                      1                                           
      Cellulitis, web-space abscess of hand                                                        1                                           
  Invasive procedure                                                                               4 (10.3)    2 (5)                 0.8      0.432
      Umbilical hernia repair                                                                      1                                           
      Amputation above knee for intractable osteomyelitis                                          1                                           
      Multiple surgery, closed trauma of the left knee                                             1                                           
      Acupuncture for weight reduction                                                             1                                           
  Immunocompromised condition                                                                      5 (12.8)    3 (7.5)               0.6      0.481
      Intravenous drug use, hepatitis C infection                                                  2                                           
      Diabetes mellitus                                                                            1                                           
      Breast cancer (surgery, radiotherapy, chemotherapy), pharyngitis                             1                                           
      Traveled to Mexico 3 months before, patent fossa ovalis                                      1                                           
  Total                                                                                            16 (41.0)   18 (45)               0.1      0.821

Clinical features
-----------------

The onset symptoms and signs of the 37 patients (2 patients\' symptoms were not reported) with infected cardiac myxoma were listed in [Table 3](#t3){ref-type="table"}. Fever was the most common symptom accounting for 97.3% of all cases. The fever nature was persistent in 2 (5.6%), recurrent in 1 (2.8%), intermittent in 1 (2.8%) and with a fever of unknown origin in 3 (8.3%) patients. In general, constitutional symptoms were more frequent than obstructive or neurological symptoms. The duration of symptoms before admission was 1.6±1.7 (range, 0.1-6; median, 1) months (*n*=21).

###### 

Onset symptoms and signs of the patients with infected cardiac myxoma

  Feature                     Present       Revankar & Clark\'s   *x*^2^   *P* value
  --------------------------- ------------- --------------------- -------- -----------
  Symptom                                                                   
      Fever                   36 (97.3)     37 (92)               0.9      0.616
      Embolic events          10 (27.0)     5 (12)                2.6      0.151
      Weight loss             9 (24.3)      13 (32)               0.6      0.460
      Dyspnea                 8 (21.6)      3 (8)                 3.1      0.106
      Fatigue                 8 (21.6)      11 (28)               0.4      0.605
      Neurologic symptoms     7 (18.9)      8 (20)                0.0      1.000
      Malaise                 6 (16.2)      11 (28)               1.4      0.279
      Rigor/shivers/chills    6 (16.2)      11 (28)               1.4      0.279
      Night sweat             5 (13.5)      11 (28)               2.3      0.165
      Weakness                3 (8.1)       5 (12)                0.4      0.713
      Abdominal pain          3 (8.1)       3 (8)                 0.0      1.000
      Anorexia                3 (8.1)                             3.4      0.106
      Edemas                  3 (8.1)                             3.4      0.106
      Chest pain/distress     2 (5.4)                             2.2      0.228
      Cough                   2 (5.4)       4 (10)                0.6      0.676
      Nausea/vomiting         2 (5.4)       1 (2)                 0.4      0.605
      Headache                1 (2.7)       4 (10)                1.7      0.360
      Arm pain                1 (2.7)                             1.1      0.481
      Arthralgia              1 (2.7)       6 (15)                3.5      0.110
      Diarrhea                1 (2.7)       3 (8)                 0.9      0.616
      Hemoptysis              1 (2.7)                             1.1      0.481
      Jaundice                1 (2.7)                             1.1      0.481
      Lethargy                1 (2.7)                             1.1      0.481
      Back pain               1 (2.7)                             1.1      0.481
      Myalgias                1 (2.7)                             1.1      0.481
      Palpitation             1 (2.7)                             1.1      0.481
      Septic shock            1 (2.7)                             1.1      0.481
  Sign                                                                      
      Temperature (°C)                                                      
        \<37.8                5/28 (17.9)   3/32 (9)              0.9      0.454
        37.8-38.9             9/28 (32.1)   19/32 (59)            4.5      0.042
        \>38.9                14/28 (50)    10/32 (31)            2.2      0.189
      Heart murmur            18 (48.6)     26 (65)               2.1      0.172
        Loud S,               3 (8.1)       14 (35)               8.1      0.006
        Extra heart sound                   9 (22)                9.4      0.002
      \"Tumor plop\"                        2 (5)                 1.9      0.494
      Splenomegaly                          3 (8)                 2.9      0.241
      Skin lesions            3 (8.1)       6 (15)                0.9      0.484
      Neurological deficits   2 (5.4)       3 (8)                 0.1      1.000

Laboratory findings showed that leukocyte count was elevated in 20 patients (76.9%) and normal in 6 (23.1%) patients (*x*^2^=15.1, *P*=0.000) with a quantitative result of 15.7±7.3 (range, 4.9-33.6; median, 15.2) ×10^9^/L (*n*=26). Hemoglobin was reduced indicating a mild anemia in 13 (92.9%) patients and normal in 1 (7.1%) patient (*x*^2^=20.6, *P*=0.000) with a quantitative result of 10.4±1.3 (range, 9-13.7; median, 10.8) g/dL (*n*=14). Erythrocyte sedimentation rate and C-reactive protein were elevated in all studied cases: erythrocyte sedimentation rate was 83.3±28.4 (range, 37-124; median, 83) mm/h (*n*=15) and C-reaction protein was 15.8±10.5 (range, 3-39.9; median, 13.2) mg/dL (*n*=17). Microscopic hematuria was present in 2 (5.4%) patients.

Microorganisms
--------------

All 39 patients had microbiological evidence confirmed by one or more investigations including blood culture, culture of resected myxoma, histopathological inspection for bacteria or confirmation by polymerase chain reaction. Blood culture for microbiological isolation was positive in 37, negative in 1 and unstated in 1. Cultures of resected myxoma tissues were done in 15 patients: 9 (60%) were positive and 6 (40%) were negative. Histopathological studies of the resected myxomas were performed in 30 patients. They were histopathologically inspected for bacteria in 14 patients: 13 (92.9%) were positive and 1 (7.1%) was negative. The 41 bacteria of 39 patients were summarized in [Table 4](#t4){ref-type="table"}.

###### 

Pathogens of infective cardiac myxoma

  Pathogens                                  Present                                Revankar & Clark\'s   *x*^2^   *P* value
  ------------------------------------------ -------------------------------------- --------------------- -------- -----------
  *Streptococci*                             17 (41.5)                              20 (50)               0.6      0.507
  *    Streptococcus viridans*               7                                                                      
  *    Streptococcus mutans*                 2                                                                      
  *    Streptococcus bovis*                  2                                                                      
  *    Streptococcus mitis*                  2                                                                      
  *    Streptococcus* (Group C)              1                                                                      
  *    Streptococcus agalactiae*             1                                                                      
  *    Streptococcus oralis*                 1                                                                      
  *    Streptococcus salivarius*             1                                                                      
  *Staphylococci*                            12 (29.3)                              7 (18)                1.6      0.295
      MSSA                                   4                                                                      
      MRSA                                   3                                                                      
  *    Staphylococcus aureus*                2 (1 was oxacillin-resistant (ORSA))                                   
  *    Staphylococcus lugdunensis*           1                                                                      
  *    Staphylococcus spp*                   1                                                                      
  *    Staphylococcus* (species not given)   1                                                                      
  *Enterococcus faecalis*                    4 (9.8)                                2 (5)                 0.7      0.675
  Gram-negative bacilli                      2 (4.9)                                3 (8)                 0.2      0.675
  *    Klebsiella pneumoniae*                2                                                                      
  Gram-negative cocci                        1 (2.4)                                                      1.0      1.000
  *    Neisseria lactamica*                  1                                                                      
  Fungus                                     1 (2.4)                                3 (8)                 1.1      0.359
  *    Histoplasma capsulatum*               1                                                                      
  Actinomyce                                 1 (2.4)                                                      1.0      1.000
  *Actinobacillus actinomycetemcomitans*     1                                                                      
  Unknown                                    3 (7.3)                                3 (8)                 0.0      1.000
      Bacterial colonies                     1                                                                      
      Gram-positive cocci                    2                                                                      

Histopathology showed inflammatory cell infiltrate in 11 (36.7%), necrosis in 4 (13.3%) and micro-/focal abscesses in 2 (6.7%) patients, respectively.

Complications
-------------

There were 12 patients in whom complications developed. Of these, embolic events in 10 (8 were multiple sites or multiple organs), sepsis in 4 (one was septic shock), disseminated intravascular coagulation in 3 and lung abscess in 1. The embolic events were shown in [Table 5](#t5){ref-type="table"}. In comparison, 18 patients of Revankar & Clark\'s^\[[@r2]\]^ series developed embolic events and only one of them were multisites (80% (8/10) *vs.* 5.6% (1/18), *x*^2^=16.3, *P*=0.000).

###### 

Embolic events.

  Location                                                                                  *n* (%)
  ----------------------------------------------------------------------------------------- ---------
  Cerebral                                                                                  1 (10)
  Cerebral, peripheral (extremities)                                                        1 (10)
  Cerebral, splenic                                                                         1 (10)
  Cerebral, splenic, renal                                                                  1 (10)
  Coronary (left anterior descending coronary artery)                                       1 (10)
  Multiple (location not indicated)                                                         1 (10)
  Multiple peripheral (left common + external iliac arteries + right deep femoral artery)   1 (10)
  Pulmonary                                                                                 1 (10)
  Splenic                                                                                   1 (10)
  Splenic, renal                                                                            1 (10)

Treatment
---------

Thirty-eight of 39 patients received a surgical treatment of infected cardiac myxoma and the reason that only patient did not undergo any surgical procedure was due to rapid deterioration leading to death. Of the 38 surgical operations, 30 were isolated cardiac myxoma resections, 5 were cardiac myxoma resection with concurrent cardiac surgical procedures (mitral valve replacement in 2, and mitral valve replacement + coronary artery bypass grafting, mitral valve replacement + embolectomy of the left anterior descending coronary artery + coronary artery bypass grafting, and pulmonary valve replacement in 1 patient each) and 3 with staged peripheral operations (3^rd^ toe of right foot amputation & right femoropoplitereal bypass; right common iliac artery thrombectomy and embolectomy of the left common and external iliac and right deep femoral arteries in 1 patient each).

The timing for surgical operation was reported in 26 patients, 4 of them were operated on an urgent basis and 22 had a delay of 18±13.5 (range, 3-42; median, 14) days (*n*=21) after admission for the purpose of sufficient preoperative antibiotic treatment and stabilization of patients\' conditions. Preoperative antibiotic treatment was described in 26 patients. The frequently used antibiotics included vancomycin (7 patients), penicillin (4 patients) and ampicillin (3 patients). Sometimes, they were used along with gentamicin (80 mg every 8 h). Other antibiotics were imipenem, meropenem, peperacillin, trimethoprim/sulfamethoxazole, oxicillin, ampicillin, nafcillin, teicoplanin, azitromicine, ceftriaxone, clindamycin and amoxicillin-clavulanic acid.

The duration of preoperative antibiotic use was 22.3±13.4 (range, 7-42; median, 18) days (*n*=12). Postoperative antibiotic regimens included vancomycin (500 mg every 6 h), ceftazidime (2 g every 8 h) and netilmicin (150 mg every 12 h) followed by cefepime (1 g every 12 h) plus teicoplanin (400 mg daily), nafcillin (2 g intravenously every 6 h) and gentamicin and antifungal drugs with a therapeutic course of 31.2±5.1 (range, 27-42; median, 28) days (*n*=9).

Outcomes
--------

During a follow-up period of 11.1±14.5 (0.1-58; median, 8.5) months (*n*=16), 37 (92.6%) patients survived and 2 (7.4%) died. Of the 37 survived patients, 35 (94.6%) were event-free and 2 (5.4%) were complicated with ruptured saccular abdominal aortic aneurysm with renal infarct and septic emboli requiring aortoiliac bypass in one patient, and increased cerebral hematoma requiring craniotomy in another. One patient died of rupture of a right lung abscess 3 weeks after admission and the other died of disseminated intravascular coagulation on postoperative day 10. The overall mortality was 5.1% and the operative mortality was 2.6%, with a significantly reduced overall mortality in comparison with that of the patient series of Revankar & Clark (overall mortality: 5.1% *vs*. 21%, *x*^2^=4.0, *P*=0.047; operative mortality: 3% *vs.* 2.6%, *x*^2^=1.4, *P*=0.239). The overall survival rate was 92.6% ([Figure 1](#f1){ref-type="fig"}). The survival rates of the surgical and non-surgical patients were 96.2% and 0%, respectively ([Figure 2](#f2){ref-type="fig"}).

![The overall survival of the present series was 92.6%.](rbccv-30-05-0571-g01){#f1}

![The survival rates of the surgical and non-surgical patients were 96.2% and 0%, respectively.](rbccv-30-05-0571-g02){#f2}

DISCUSSION
==========

In 1998, Revankar & Clark^\[[@r2]\]^ defined infected cardiac myxoma in three levels based on clinical and pathological findings of the myxoma:

Definite infected cardiac myxoma

1.  1\. Documented myxoma by pathology and

2.  2a. Microorganisms seen on pathology or

3.  2b. Positive blood cultures and inflammation on pathology.

Probable infected cardiac myxoma

1.  Documented myxoma by pathology and

2.  Positive blood cultures or inflammation on pathology.

Possible infected cardiac myxoma

1.  Characteristic appearance by transthoracic or transesophageal echocardiography and

2.  Positive blood cultures.

Using these criteria, the three-level infected cardiac myxoma accounted for 85%, 12.5% and 2.5% respectively as reported by Revankar & Clark^\[[@r2]\]^, and 87.2%, 10.3% and 2.6% in the present series.

The diagnosis of infected cardiac myxoma can be a challenge. The time interval from symptom onset to establishment of the diagnosis varied from 0 to 126 (median, 4) months^\[[@r40]\]^. Pathogens can be evidenced by blood culture, culture or staining of resected myxoma, and occasionally confirmation by polymerase chain reaction is helpful. The transthoracic or transesophageal echocardiography is a reliable means for the detection of a cardiac myxoma. Only in patients with rapid deterioration leading to sudden death was the diagnosis of a cardiac myxoma established by autopsy.

Comparisons between the two series revealed that the present series were characterized by few occasions of moderate-grade fever (while more occasions of high-grade fever in spite of lack of a statistical significance) and abnormal heart sound, but more uncommon microorganisms and more severe complications \-- multiple embolic events. Other clinical features of the two patient series did not differ from each other. The somehow aggravated situations may contribute to the presence of refractory microorganisms, such as Gram-negative bacteria, fungus and actinomyce.

In comparison with Revankar & Clark\'s^\[[@r2]\]^ series, the present series disclosed a significantly decreased overall mortality. It is believed that refinement of the prompt diagnosis and timely management (use of sensitive antibiotics and surgical resection of the infected myxoma) have resulted in better outcomes of such patients.

CONCLUSION
==========

In conclusion, the present series of infected cardiac myxoma illustrated somehow aggravated clinical manifestations (relative more occasions of high-grade fever, multiple embolic events and the presence of refractory microorganisms), which should draw sufficient attention to be careful in the diagnosis and treatment. In general, the prognosis of infected cardiac myxoma is relative benign and now the long term survival is always promising.
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